Lv1
70 积分 2021-06-28 加入
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
4个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
4个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
4个月前
已完结
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects
4个月前
已完结
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
4个月前
已完结
Multiple myeloma
4个月前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
5个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
5个月前
已完结
多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)
6个月前
已完结
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
6个月前
已完结
皖公网安备34019202002308
